Here is why Vaxcyte Inc. (PCVX) stock slid down on Wednesday?

Vaxcyte Inc. (PCVX) shares plunged 8.05% in after-hours on Wednesday, January 12, 2022, and closed the daily trading at $20.23. Even in the regular trading session of Wednesday, PCVX’s stock lost 6.82%. PCVX shares have fallen 14.73% over the last 12 months, and they have moved down 7.99% in the past week. Over the past three months, the stock has lost 9.47%, while over the past six months, it has gained 7.37%.

Let’s have a brief discussion about its recent news and developments.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

>> 7 Top Picks for the Post-Pandemic Economy << 

PCVX proposed a public offering of common stock

On January 12, 2022, Vaxcyte, Inc. (PCVX), commenced an underwritten public offering of its common stock and pre-funded warrants. Vaxcyte intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of its common stock offered in the public offering.

Read More

FDA accepted PCVX IND for VAX-24

On January 06, 2022, the U.S. Food and Drug Administration (FDA) cleared the Investigational New Drug (IND) application for VAX-24, which is a PCVX lead, 24-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease.

Vaxcyte expects to initiate the VAX-24 Phase 1/2 clinical study in adults in the first quarter of 2022 and announce topline immunogenicity results by the end of the year.

PCVX latest financial results

On November 10, 2021, Vaxcyte, Inc. (PCVX), reported financial results for the third quarter ended September 30, 2021.

Q3 2021 financial highlights

  • PCVX reported zero revenue for Q3 2021.
  • General and administrative expenses were $6.5 million for the three months ended September 30, 2021, as compared to $4.9 million for the same period in 2020.
  • Research and development expenses were $20.4 million for the third quarter of 2021 compared to $16.4 million in Q3 2020.
  • It suffered a net loss of $26.6 million or net loss per share of $0.51 in Q3 2021 compared to $21.0 million or net loss per share of $0.41 for the same period in 2020.
  • The company ended the third quarter with cash, cash equivalents, and investments of $318.3 million compared to $386.2 million as of December 31, 2020.

    >> 7 Top Picks for the Post-Pandemic Economy << 


The proposed public offering of common stock was the reason behind its plummeting on Wednesday and we can expect it to further decline in the coming trading sessions on Thursday.

Most Popular

Related posts